
Ernexa Therapeutics Ernexa Therapeutics, is a publicly traded, preclinical-stage company focused on using cutting-edge gene-editing tools to deliver highly innovative, effective, and safe off-the-shelf cell therapies for the treatment of advanced solid tumors. Our core technology utilizes best-in-class approach to engineer allogenic induced pluripotent stem cells (iPSCs) to express genes of interest and to efficiently differentiate these cells into mesenchymal stem cells (iMSCs). We seek to capitalize on the intrinsic tumor-homing ability of MSCs to slip through the tumor’s defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment (TME), thus unleashing potent anti-cancer immune responses. Currently, we are focusing on developing iPSC-derived iMSC that express critical factors, such as pro-inflammatory cytokines. Ernexa entered into an exclusive license and collaboration agreement with Factor Bioscience Limited in September 2024 and with this agreement, Ernexa is transforming itself to a product-based developmental stage company. Therapeutic Developer

Ernexa Therapeutics

Ernexa Therapeutics, is a publicly traded, preclinical-stage company focused on using cutting-edge gene-editing tools to deliver highly innovative, effective, and safe off-the-shelf cell therapies for the treatment of advanced solid tumors. Our core technology utilizes best-in-class approach to engineer allogenic induced pluripotent stem cells (iPSCs) to express genes of interest and to efficiently differentiate these cells into mesenchymal stem cells (iMSCs). We seek to capitalize on the intrinsic tumor-homing ability of MSCs to slip through the tumor’s defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment (TME), thus unleashing potent anti-cancer immune responses. Currently, we are focusing on developing iPSC-derived iMSC that express critical factors, such as pro-inflammatory cytokines. Ernexa entered into an exclusive license and collaboration agreement with Factor Bioscience Limited in September 2024 and with this agreement, Ernexa is transforming itself to a product-based developmental stage company.

Therapeutic Developer